PHAT Live signals | Maximize Profits with Getagraph.com

BUY 94197 min ago

@ $6.57

Issued: 14 Feb 2024 @ 13:56

Return: 36.53%

Previous signal: Feb 13 - 15:47

Previous signal: Sell

Return: 5.80 %

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases...

Stats
Today's Volume	590 237
Average Volume	901 668
Market Cap	524.54M
EPS	$0 ( 2024-03-07 )
Next earnings date	( $-1.130 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.28
ATR14	$0.0160 (0.18%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-08	Henderson Molly	Sell	3 435	Common Stoock
2024-03-22	Curran Terrie	Sell	16 851	Common Stock
2024-01-24	Medicxi Ventures Management (jersey) Ltd	Buy	0	Common Stock
2024-01-24	Medicxi Ventures Management (jersey) Ltd	Buy	0	Common Stock
2024-01-24	Medicxi Ventures Management (jersey) Ltd	Buy	0	Common Stock

INSIDER POWER
-49.16
Last 93 transactions
Buy: 9 929 521 \| Sell: 11 759 720

Volume Correlation

Long: 0.04 (neutral)

Short: -0.90 (very strong negative)

Signal:(36.086) Neutral

Phathom Pharmaceuticals Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Phathom Pharmaceuticals Correlation - Currency/Commodity

0.07
( neutral )

-0.03
( neutral )

0.00
( neutral )

0.60
( weak )

0.46
( neutral )

-0.21
( neutral )

Phathom Pharmaceuticals Financials

Annual	2023
Revenue:	$682 000
Gross Profit:	$515 000 (75.51 %)
EPS:	$-3.93

Q4	2023
Revenue:	$682 000
Gross Profit:	$905 000 (132.70 %)
EPS:	$-1.390

Q3	2023
Revenue:	$0
Gross Profit:	$-121 000 (0.00 %)
EPS:	$-0.760

Q2	2023
Revenue:	$0
Gross Profit:	$-123 000 (0.00 %)
EPS:	$-0.840

Financial Reports:

No articles found.

Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.